       Document 0245
 DOCN  M9630245
 TI    Systemic administration of 2-chloro-2'-deoxyadenosine (2-CdA) in
       patients with systemic scleroderma.
 DT    9603
 AU    Majewski S; Skopinska M; Blaszczyk M; Ryba M; Grieb P; Chorzelski T;
       Jablonska S; Department of Dermatology, Medical Academy, Warsaw, Poland.
 SO    Arch Immunol Ther Exp (Warsz). 1994;42(1):33-4. Unique Identifier :
       AIDSLINE MED/96120317
 AB    Three patients with diffuse variety of systemic scleroderma were treated
       with 2-chloro-2'-deoxyadenosine. In two of them a moderate improvement
       of skin involvement was observed. No significant effects of the drug on
       the immunological parameters have been found.
 DE    Cladribine/*ADMINISTRATION & DOSAGE  CD4-Positive T-Lymphocytes/DRUG
       EFFECTS/IMMUNOLOGY  CD8-Positive T-Lymphocytes/DRUG EFFECTS/IMMUNOLOGY
       Drug Administration Schedule  Female  Human  Immunosuppressive
       Agents/*ADMINISTRATION & DOSAGE  Infusions, Intravenous  Male  Middle
       Age  Scleroderma, Systemic/*DRUG THERAPY/IMMUNOLOGY  T-Lymphocyte
       Subsets/DRUG EFFECTS  CLINICAL TRIAL  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).

